Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced Soft-tissue Sarcoma Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Soft Tissue Sarcoma
Interventions
Temozolomide
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2007 · Synced May 22, 2026, 2:44 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Panitumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
Interventions
ziv-aflibercept
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer
Interventions
Lonafarnib, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Sarcoma
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
Interventions
AG-120
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma
Interventions
ATX-101
Drug
Lead sponsor
Benjamin Izar
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
Interventions
Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
Interventions
Balstilimab, Zalifrelimab, Doxorubicin, Botensilimab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 2:44 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Immunolight, LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide, Autologous CAR Positive T cells
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2032
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced May 22, 2026, 2:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
TH-302
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
Tucson, Arizona • Santa Monica, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Interventions
CAR-GPC3 T Cells
Biological
Lead sponsor
Sotio Biotech Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
5
States / cities
Newport Beach, California • Dallas, Texas • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 22, 2026, 2:44 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced May 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ribociclib, Everolimus
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced May 22, 2026, 2:44 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ADCT-601, Gemcitabine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 22, 2026, 2:44 AM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
Interventions
Selinexor, Ixazomib
Drug
Lead sponsor
Matthew Ingham
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced May 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Colon Cancer, Recurrent Malignant Mesothelioma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Colon Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Colon Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced May 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced May 22, 2026, 2:44 AM EDT